Breaking News, Collaborations & Alliances

Theragent to Provide Manufacturing and Testing Services for CellVax

CellVax’s novel cancer immunotherapy candidate FK-PC101 is entering Phase 2 clinical trials.

Author Image

By: Charlie Sternberg

Associate Editor

Theragent, a cell therapy contract development and manufacturing organization (CDMO) focused on advancing next-generation cancer and rare disease treatments, has been selected by CellVax Therapeutics to provide manufacturing and testing services for CellVax’s novel cancer immunotherapy candidate FK-PC101 entering Phase 2 clinical trials. FK-PC101 is a cell-based autologous cancer vaccine for prostate cancer patients who have a high risk of recurrence after prostatectomy.   Theragent and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters